NASDAQ:XBIO

Xenetic Biosciences Stock Predictions

etoro logo Buy XBIO
*Your capital is at risk
$3.34
-0.0400 (-1.18%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

XBIO Prediction Chart

XBIO Predictions History

Latest community submissions for XBIO.
Predictor Target Session Target Price Result Direction Accuracy Score
Rybkarybka Rybkarybka Merchant
Nov 1, 2021 $1.75 -90.11% $1.77 X 98.87% 2
JS JS Pro
Oct 28, 2021 Bearish $1.69 V 0
Rybkarybka Rybkarybka Merchant
Oct 28, 2021 $1.74 -89.70% $1.69 X 97.04% 1
Rybkarybka Rybkarybka Merchant
Oct 15, 2021 $1.94 -89.22% $1.80 X 92.22% 0
JS JS Pro
Oct 12, 2021 $2.00 -89.53% $1.91 X 95.29% 0
Rybkarybka Rybkarybka Merchant
Oct 12, 2021 $2.22 -88.38% $1.91 X 83.77% 0
Rybkarybka Rybkarybka Merchant
Oct 11, 2021 $2.01 -89.74% $1.96 X 97.45% 1
JS JS Pro
Oct 7, 2021 $1.92 -89.62% $1.85 X 96.22% 0
Rybkarybka Rybkarybka Merchant
Oct 7, 2021 $1.96 -89.41% $1.85 X 94.05% 0
Rybkarybka Rybkarybka Merchant
Oct 5, 2021 $2.00 -89.07% $1.83 X 90.71% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for XBIO with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT XENETIC BIOSCIENCES INC
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE